Background:

*Mycoplasma bovis* has become a significant bacterial pathogen in commercial feedlots over the past decade or so. Since *Mycoplasma* bacteria lack a cell wall, antibiotics (which disturb bacterial cell walls) are not very effective for treating cattle infected with these bacteria. M. bovis is involved in bovine respiratory disease complex (BRD), and also plays a role in chronic pneumonia and polyarthritis syndrome (CPPS) in high-risk fall-placed feedlot calves. This syndrome has emerged as a leading cause of mortality in feedlot calves in Western Canada.

Recent research has demonstrated that antimicrobial peptides possess antibacterial and immune system boosting properties. These peptides are part of an animal’s immune system and act directly upon bacteria.

Objectives:

To determine if small chains of amino acids known as antimicrobial peptides in combination with a Mycoplasma bovis antigen can protect against mycoplasma by stimulating a stronger immune response in newborn calves.

What They Did:
The researchers examined, in detail, the methods by which \textit{M. bovis} affects various immune system functions. With that knowledge, they constructed a series of antigen-antimicrobial peptide combinations, and tested their effectiveness on \textit{M. bovis} in culture. A proof of concept trial was then performed to test the different combinations in live cattle infected with \textit{mycoplasma}. The animals were immunized twice, 21 days apart and the animals exhibiting the best immune response to the vaccine were transported to the VIDO research farm. Animals were re-immunized 21 days later and all animals were euthanized and necropsied.

What They Learned:

The researchers discovered that \textit{mycoplasma} acts on healthy cells in a number of ways. These include inhibiting apoptosis (programmed cell death) of peripheral blood mononuclear cells (white blood cells that play a critical role in immune response), prolonging the life of the cell, which in turn facilitates the spread of \textit{M. bovis} throughout various tissues. In addition, \textit{M. bovis} can invade and replicate inside red blood cells without damaging or affecting the function of those cells, opening another transport mechanism by which \textit{M. bovis} can spread. \textit{M. bovis} also creates biofilms, which means the cells stick together on a surface. These biofilms are another way that \textit{M. bovis} evades animal immune responses.

In the preliminary animal trial that tested the pilot vaccine, all treatment groups experienced weight losses, with only a few animals able to regain most of that weight by the end of the trial. Likewise, all animals experienced some temperature increases, and only the surviving animals showed a return to normal temperatures. Survival rates were not statistically different between treatment groups and the control, and similar degrees of lung lesions were observed between all groups. \textit{M. bovis} was found in lung tissue (both healthy and diseased) in all animals, and in one animal with obvious signs of arthritis. It was also found in the blood of 9 out of the 20 animals. Other common pathogens associated with respiratory disease such as \textit{A. haemolytica} and \textit{P. haemolytica} were also found in some of the lungs of the challenge animals, which may have impacted the effectiveness of the vaccine combinations administered.

What It Means:

While this study was able to find an antigen-antimicrobial peptide combination that stimulated an immune response against \textit{mycoplasma} in a challenge situation, the boost in immunity was not strong enough to prevent disease.

Developing an effective vaccine against \textit{mycoplasma} by triggering the animal’s immune response to destroy \textit{M. bovis} is extremely challenging. It is unclear what causes some animals to develop severe, fatal pneumonia or COPPS while others infected with \textit{mycoplasma} remain perfectly healthy. Also, there are numerous different strains of \textit{M. bovis}, and it is usually present with a host of other respiratory disease-related pathogens that can still cause disease. \textit{M. bovis} does not have a cell wall, many antibiotics are not effective for treatment; although \textit{M. bovis} strains have been shown to be sensitive to oxy- or chlortetracycline, enrofloxacin (Baytril), and tulathromycin (Draxxin – the only drug currently with a label claim for mycoplasma). However, antibiotic treatment does not prevent the spread of \textit{M. bovis} from the apparently healthy carriers, and can be very expensive.

Although some vaccines against \textit{mycoplasma} have been approved in the United States, none have been approved in Canada, and very little published data exists to support their effectiveness. The single recently published study we were able to find compared two commercial \textit{mycoplasma} vaccines in veal calves, and found the vaccine efficacy to be 64% for one and less than 1% for the other.

Research is continuing to try to find new ways (vaccine based and other avenues) to effectively prevent and treat \textit{mycoplasma} infections in cattle.

Proudly Funded By: